VP
venBio Partners Portfolio holdings
AUM
$115M
This Quarter Return
-22.27%
1 Year Return
-33.99%
3 Year Return
+221.07%
5 Year Return
+224.54%
10 Year Return
–
AUM
$847M
AUM Growth
+$847M
(-19%)
Cap. Flow
+$48.8M
Cap. Flow
% of AUM
5.76%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
10
New
2
Increased
–
Reduced
2
Closed
–
Top Buys
| 1 |
ELEV
Elevation Oncology
ELEV
|
$35.4M |
| 2 |
IMPL
Impel Pharmaceuticals Inc. Common Stock
IMPL
|
$24.4M |
Top Sells
| 1 |
Akero Therapeutics
AKRO
|
$6.04M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$4.99M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
ALX Oncology
ALXO
$62.7M
| $530M | 62.6% | 9,699,925 | – | – |
|
2
Harmony Biosciences
HRMY
$2.12B
| $98.9M | 11.68% | 3,504,624 | – | – |
|
|
3
Akero Therapeutics
AKRO
$3.74B
| $54.6M | 6.44% | 2,200,778 -243,533 | -10% | -$6.04M |
|
4
Pharvaris
PHVS
$1.39B
| $42.9M | 5.06% | 2,303,310 | – | – |
|
|
ELEV
5
DELISTED
Elevation Oncology
ELEV
| $35.4M | 4.18% | +2,608,167 | New | +$35.4M |
|
|
6
Apellis Pharmaceuticals
APLS
$3.48B
| $26M | 3.07% | 411,471 -79,000 | -16% | -$4.99M |
|
|
IMPL
7
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
| $24.4M | 2.88% | +2,759,791 | New | +$24.4M |
|
|
CMPI
8
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
| $21.9M | 2.58% | 3,673,374 | – | – |
|
|
MTCR
9
DELISTED
Metacrine, Inc. Common Stock
MTCR
| $11.6M | 1.37% | 3,059,123 | – | – |
|
|
VRNA
10
Verona Pharma
VRNA
$9.16B
| $1.06M | 0.13% | 161,897 | – | – |
|